New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
07:02 EDTCARACara Therapeutics 5M share IPO priced at $11.00
The deal priced at the bottom of the $11.00-$13.00 range. Stifel and Piper Jaffray acted as joint book running managers for the offering.
News For CARA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
08:08 EDTCARACara Therapeutics completes enrollment of Phase 2 trial of I.V. CR845
Cara Therapeutics announced that it has completed enrollment in its Phase 2 proof-of-concept trial of its lead kappa opioid agonist, CR845, for the treatment of uremic pruritus, or UP. The Phase 2 study is a double]blind, randomized, placebo]controlled trial designed to evaluate the efficacy of I.V. CR845 compared to placebo in reducing the intensity of itch in dialysis patients over a two-week dosing period. The primary endpoint of the study is the change from baseline of the average worst itching during the second week of treatment, as recorded on a visual analog scale. Secondary endpoints focus on quality of life measures associated with pruritus burden using a series of previously validated self-assessment scales. The study enrolled 65 dialysis patients at multiple sites in the U.S. A previously completed Phase 1 study of CR845 in 24 dialysis patients indicated that I.V. CR845 was safe and well-tolerated, and exhibited dose-linear pharmacokinetics across a five-fold dose range.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use